Aims

“Clinical Trials” does represent part of the thalidomide heritage, for that unhappy chapter in the history of drug therapy called into question not only the legal framework within which medicines were developed and marketed but also the techniques which then existed for establishing the efficacies of new treatment procedures. The years that followed saw the establishment in many countries of elaborate, and on the whole effective, legislative provisions for the control of drug testing. This trend was paralleled by the introduction of increasingly sophisticated techniques for comparing and contrasting new and existing medications. In “Clinical Trials” we have attempted to bring together the main themes associated with testing drugs and other therapeutic techniques (Preface, page xi).

Contents (xvi+212 pages)
Foreword (Lord Cohen of Birkenhead)
Preface (Neil and Susan Johnson)
List of contributors
1. The safety of medicines: the control of clinical trials (TRM Simon, G Jones)
2. From laboratory to clinical use (DT Greenwood, AH Todd)
3. Organisation of clinical trials: the pretrial period (FN Johnson, S Johnson)
4. Organisation of clinical trials: the trial period and after (FN Johnson, S Johnson)
5. Statistical analysis of clinical trial data (S Ambler)
6. Sequential analysis in clinical trials (K McPherson)
7. Interpretation of clinical trials (PM Levy)
8. Psychological factors in clinical trials (R Gilmour)
9. Ethical aspects of drug evaluation (RN Smith)
10. Clinical trials in general practice (JE Murphy)
11. Surgical trials (CJL Strachan, GD Oates)
12. Epilogue: future trends in clinical trial research (FN Johnson, S Johnson)

Index

Authors

The editors are F Neil Johnson (Senior Lecturer in Psychology at the University of Lancaster, England, and Susan Johnson, formerly Research Fellow in Cancer Studies at the University of Birmingham Medical School, England. The foreword is by Lord Cohen of Birkenhead CH.
The contributors are S Ambler (Lecturer in Psychology, Department of Psychology, University of Lancaster, Lancaster, England); R Gilmour (Lecturer in Psychology, Department of Psychology, University of Lancaster, Lancaster, England); DT Greenwood (Research (Biology) Department, Imperial Chemical Industries Ltd, Macclesfield, Cheshire, England); G Jones (Senior Medical Officer, Department of Health and Social Security, Medicines Division, London, England); PM Levy (Professor of Psychology, Department of Psychology, University of Lancaster, Lancaster, England); K McPherson (Lecturer, Department of Social and Community Medicine, University of Oxford, Oxford, England); JE Murphy (Editor: Journal of International Medical Research); GD Oates (Consultant Surgeon, General Hospital, Birmingham, England); TRM Simon (Secretary, Committee on Safety of Medicines, London, England); RN Smith (Head of Clinical Research, Roche Products Ltd, Welwyn Garden City, Hertfordshire, England); CJL Strachan (Senior Lecturer, Department of Surgery, University of Birmingham, and Honorary Consultant Surgeon, Queen Elizabeth Hospital, Birmingham, England); and, AH Todd (Development Department, Imperial Chemical Industries Ltd, Macclesfield, Cheshire, England).